In summary, finotonlimab, a novel, humanized anti-PD-1 monoclonal antibody, demonstrates high affinity for PD-1 with lower Fc-mediated function and exhibits a durable PK/PD profile and significant in vivo anti-tumor activity. Here, PDCD1 is linked to neoplasm.